Myriad Assures Investors of Strong Patent Position Despite ACLU Anti-Gene Patenting Lawsuit
March 10, 2010
Myriad Assures Investors of Strong Patent Position Despite ACLU Anti-Gene Patenting Lawsuit
According to CEO Peter Meldrum, Myriad’s strong IP position on the BRACAnalysis test and a large internal database of BRCA mutations ensure that "regardless of the outcome of this particular lawsuit, it will not have a material adverse effect on the company … or on the future revenues of our products."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Healthcare Providers Petition Myriad to Add Large Rearrangement Analysis to Standard BRACAnalysis
August 3, 2011 / Pharmacogenomics Reporter - Myriad Defends Policy of Urging Docs to Genetically Counsel BRACAnalysis Customers
February 10, 2010 / Pharmacogenomics Reporter - SCOTUS Justices Struggle to Draw Line between Isolated DNA, cDNA in Gene Patent Hearing
April 17, 2013 / Pharmacogenomics Reporter - GenomeWeb Feature: Regardless of Gene Patent Challenges, Myriad Faces Shifting Competitive Landscape
April 17, 2013 / Pharmacogenomics Reporter - USPTO Hearing on Confirmatory Gene Testing Raises Calls for Reform Outside Patent System
February 22, 2012 / Pharmacogenomics Reporter